清髓剂量预处理异基因造血干细胞移植治疗年龄≥155岁高危恶性血液系统疾病12例临床分析
Clinical studies of myeloablative dose conditioning prior to allogeneic hematopoietic stem cell transplantation for treatment of 12 patients over 55 years with high-risk malignant blood diseases
摘要
高龄恶性血液系统疾病患者对化疗反应差、缓解率低、复发率高,且治疗过程中合并症多、治疗相关死亡率高,复杂染色体核型、继发原因等高危因素多。异基因造血干细胞移植(allo-HSCT)是有效的治疗手段,但是移植相关死亡率(TRM)高。我们采用清髓剂量预处理方案对12例年龄≥55岁高危恶性血液系统疾病患者进行allo-HSCT,现报告如下。
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2016年第8期708-711,共4页
Chinese Journal of Hematology
参考文献15
-
1成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2011年版)[J].中华血液学杂志,2011,32(11):804-807. 被引量:183
-
2无,吴德沛,阮长耿.骨髓增生异常综合征诊断与治疗专家共识[J].中华血液学杂志,2012,33(4):347-352. 被引量:75
-
3Sorror ML,Maris MB,Storb R,et al.Hematopoietic cell trans- plantation (HCT)- specific comorbidity index:a new tool for risk assessment before allogeneic HCT[J].Blood,2005,106(8):2912-2919.
-
4Nazha A,Ravandi F.Acute myeloid leukemia in the elderly:do we know who should be treated and how?[J].Leuk Lymphoma,2014,55(5):979-987.
-
5McClune BL,Weisdorf DJ,Pedersen TL,et al.Effect of age on outcome of reduced- intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome[J].J Clin Oncol,2009,28(11):1878-1887.
-
6Koreth J,Aldridge J,Kim HT,et al.Reduced-intensity condition- ing hematopoietic stem cell transplantation in patients over 60 years:hematologic malignancy outcomes are not impaired in ad- vanced age[J].Biol Blood Marrow Transplant,2010,16(6):792-800.
-
7Brunner AM,Kim HT,Coughlin E,et al.Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies[J].Biol Blood Marrow Transplant,2013,19(9):1374-1380.
-
8Sorror ML,Sandmaier BM,Storer BE,et al.Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation[J].J Clin Oncol,2007,25(27):4246-4254.
-
9Shimoni A,Nagler A.Optimizing the conditioning regimen for allogeneic stem- ceil transplantation in acute myeloid leukemia; dose intensity is still in need[J].Best Pract Res Clin Haematol,2011,24(3):369-379.
-
10Blaise D,Castagna L.Do different conditioning regimens really make a difference?[J].Hematology Am Soc Hematol Educ Program,2012:237-245.
二级参考文献8
-
1Arellano ML, Langston A, Winton E, et al. Treatment of relapsed acute leukemia after allogeneie transplantation : a single center experience. Biol Blood Marrow Transplant,2007,13 : 116-123.
-
2Prigozhina T, Gnrevitch O, Slavin S. Non-myeloablative conditioning to induce tolerance after allogeneic bone marrow transplantation in mice. EXP Hematol, 1999,27 : 1503.
-
3Carella AM, Cavaliere M, Lerma E, et al. Autografting followed by non- myeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietie stem-cell transplantation as treatment of resistant Hodgkins' disease and non-Hedgkins' lymphoma. J Clin Oncol, 2000,18:3918-3924.
-
4Giralt S. Reduced-intensity conditioning regimens for hematologic malignancies:what have we learned over the last 10 years? Hematology Am Soc Hematol Educ Program,2005:384-389.
-
5Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant, 1995,15:825-828.
-
6Schulman HM, Sullivan KM, Weiden PL, et al, Chronic graft-versus-host syndrome in man. A long term clinic opathologic study of Seatle patients. Am J Med, 1980,69:204-217.
-
7Alyea EP, Kim PIT, Ho V ,et al. Comparative outcome of non-myeloablatire and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood,2005,105:1810-1814.
-
8Bachanova V, Verneris MR, DeFor T, et al. Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Bleed, 2009, 113: 2902-2905.
共引文献250
-
1贾雯,曹文娟,郭书芳,宋艳艳.口服复方黄黛片联合ATRA对急性早幼粒细胞白血病(APL)患儿的有效性及安全性探究[J].中国合理用药探索,2019,0(12):143-145.
-
2朱莉.急性白血病患者CAR-T治疗的护理体会[J].实用临床护理学电子杂志,2020,0(3):148-148. 被引量:1
-
3连成,雷平冲,刘艳慧.血清ACLY和IL-8及CD64在急性髓系白血病中的表达水平及其与感染预后关系[J].热带医学杂志,2023,23(12):1724-1727.
-
4解菊芬,邢志华,冯建伟.急性髓系白血病M2型的临床特征及预后因素分析[J].世界最新医学信息文摘,2019,0(103):67-68.
-
5张飞,戚玉杨,陈丽丽,杨娜,吴光启.不同剂量地西他滨联合减剂量HAG治疗中高危MDS及老年AML患者的有效性和安全性回顾分析[J].哈尔滨医科大学学报,2023,57(2):169-172. 被引量:1
-
6齐欣欣,朱海宏,马伟伟.健康宣教标准路径对老年急性髓系白血病治疗期间的影响观察[J].哈尔滨医药,2020(5):469-470. 被引量:1
-
7吴小津,马骁,刘跃均,赵晔,胡晓慧,周海侠,韩悦,唐晓文,付铮铮,仇惠英,孙爱宁,吴德沛.异基因造血干细胞移植治疗50岁以上恶性血液病患者35例[J].中华器官移植杂志,2011,32(8):485-487. 被引量:3
-
8冯佳,柳金,庞丽萍,温娟娟,钟凤鸾,张倩,孟庆祥.吡柔比星巩固治疗急性早幼粒细胞白血病疗效研究[J].中国肿瘤临床,2012,29(12):861-863. 被引量:1
-
9于淑梅.沙利度胺治疗骨髓增生异常综合征20例的临床疗效观察[J].按摩与康复医学,2012,3(30):42-43. 被引量:1
-
10邵英起,李星鑫,葛美丽,施均,张静,黄金波,黄振东,聂能,郑以州.抗胸腺细胞球蛋白/抗淋巴细胞球蛋白治疗345例重型再生障碍性贫血患者的长期随访研究[J].中华血液学杂志,2013,34(1):30-35. 被引量:11
-
1许兰平,韩婷婷.异基因造血干细胞移植术后移植物抗宿主病的研究进展[J].临床内科杂志,2011,28(11):725-728. 被引量:4
-
2杨晶晶,胡燕.外周中心静脉置管用于恶性血液系统疾病30例及其护理[J].中国药业,2015,24(B12):306-308.
-
3石磊,郑春荣,刘凤霞.健康教育对提高白血病病人化学治疗认知程度的调查[J].吉林医学,2004,25(5):43-44.
-
4张晓燕.恶性血液病医院感染分析与护理[J].浙江实用医学,2002,7(1):57-58.
-
5肖毅,张义成,刘文励.异基因造血干细胞移植后闭塞性细支气管炎的诊断及治疗[J].中国医师进修杂志,2007,30(10):71-72. 被引量:1
-
6陈欢.造血干细胞移植治疗老年急性髓性白血病[J].国际输血及血液学杂志,2009,32(2):105-108.
-
7李新,邱录贵.HLA半相合造血干细胞移植的研究进展[J].中华血液学杂志,2005,26(6):382-384. 被引量:9
-
8汪笑秋,江锦红,曲志刚,马光丽,刘永华,章俏雷,王晓丽,金伟媚,方炳木.造血干细胞移植术后并发弥漫性肺泡出血三例[J].中华急诊医学杂志,2015,24(11):1290-1292. 被引量:1
-
9姜义荣,马道新,陈学良,刘春生.自杀基因在异基因骨髓移植中的应用[J].国外医学(肿瘤学分册),2003,30(4):311-314. 被引量:1
-
10徐丽,容娟,陈琳.异基因造血干细胞移植后闭塞性细支气管炎综合征病人的护理[J].护理研究(中旬版),2010,24(4):996-997. 被引量:1